Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01572038




Registration number
NCT01572038
Ethics application status
Date submitted
3/04/2012
Date registered
5/04/2012
Date last updated
25/09/2020

Titles & IDs
Public title
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Scientific title
A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
Secondary ID [1] 0 0
2011-005334-20
Secondary ID [2] 0 0
MO28047
Universal Trial Number (UTN)
Trial acronym
PERUSE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Docetaxel
Treatment: Drugs - Nab-paclitaxel
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Pertuzumab
Treatment: Drugs - Trastuzumab

Experimental: Pertuzumab + Trastuzumab + Taxane - Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.


Treatment: Drugs: Docetaxel
Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Treatment: Drugs: Nab-paclitaxel
Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Treatment: Drugs: Paclitaxel
Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

Treatment: Drugs: Pertuzumab
Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.

Treatment: Drugs: Trastuzumab
Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
Timepoint [1] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [2] 0 0
Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
Timepoint [2] 0 0
The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Primary outcome [3] 0 0
Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
Timepoint [3] 0 0
The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Primary outcome [4] 0 0
Number of Participants With Grade =3 Treatment-Emergent Adverse Events, Occurring in =1% of Participants by System Organ Class and Preferred Term
Timepoint [4] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [5] 0 0
Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in =10% of Participants by System Organ Class
Timepoint [5] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [6] 0 0
Number of Participants With Grade =3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in =0.5% of Participants by Preferred Term
Timepoint [6] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [7] 0 0
Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in =0.2% of Participants by Preferred Term
Timepoint [7] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [8] 0 0
Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in =0.5% of Participants by Preferred Term
Timepoint [8] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [9] 0 0
Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in =5% of Participants by Category
Timepoint [9] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [10] 0 0
Number of Participants With Grade =3 Treatment-Emergent Adverse Events to Monitor, Occurring in =0.5% of Participants by Category and Preferred Term
Timepoint [10] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [11] 0 0
Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term
Timepoint [11] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [12] 0 0
Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [12] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [13] 0 0
Subgroup Analysis by Age (=65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade =3 TEAEs, Any-Grade and Grade =3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
Timepoint [13] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [14] 0 0
Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade =3 TEAEs, Any-Grade and Grade =3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
Timepoint [14] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [15] 0 0
Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [15] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [16] 0 0
Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [16] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [17] 0 0
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [17] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [18] 0 0
Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [18] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [19] 0 0
Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade =3 TEAEs, and Grade =3 TEAEs Related to Pertuzumab
Timepoint [19] 0 0
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [20] 0 0
Number of Participants With a Congestive Heart Failure Event
Timepoint [20] 0 0
From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [21] 0 0
Time to Onset of the First Episode of Congestive Heart Failure
Timepoint [21] 0 0
From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [22] 0 0
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
Timepoint [22] 0 0
Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [23] 0 0
Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study
Timepoint [23] 0 0
Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [24] 0 0
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
Timepoint [24] 0 0
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [25] 0 0
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
Timepoint [25] 0 0
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [26] 0 0
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
Timepoint [26] 0 0
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Primary outcome [27] 0 0
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
Timepoint [27] 0 0
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [1] 0 0
Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Timepoint [1] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [2] 0 0
Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [2] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [3] 0 0
Subgroup Analysis by Age (=65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [3] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [4] 0 0
Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [4] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [5] 0 0
Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [5] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [6] 0 0
Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [6] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [7] 0 0
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [7] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [8] 0 0
Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [8] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [9] 0 0
Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Timepoint [9] 0 0
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [10] 0 0
Overall Survival
Timepoint [10] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [11] 0 0
Subgroup Analysis by Region of Enrollment: Overall Survival
Timepoint [11] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [12] 0 0
Subgroup Analysis by Age (=65 vs. >65 Years): Overall Survival
Timepoint [12] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [13] 0 0
Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival
Timepoint [13] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [14] 0 0
Subgroup Analysis by Taxane Chemotherapy: Overall Survival
Timepoint [14] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [15] 0 0
Subgroup Analysis by Visceral Disease at Baseline: Overall Survival
Timepoint [15] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [16] 0 0
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival
Timepoint [16] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [17] 0 0
Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival
Timepoint [17] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [18] 0 0
Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival
Timepoint [18] 0 0
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [19] 0 0
Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Timepoint [19] 0 0
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [20] 0 0
Percentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1
Timepoint [20] 0 0
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [21] 0 0
Subgroup Analysis by Age (=65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Timepoint [21] 0 0
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [22] 0 0
Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Timepoint [22] 0 0
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [23] 0 0
Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1
Timepoint [23] 0 0
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [24] 0 0
Duration of Response as Assessed by the Investigator Using RECIST v1.1
Timepoint [24] 0 0
From date of first confirmed response (CR or PR) to first documented disease progression or death from any cause, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [25] 0 0
Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1
Timepoint [25] 0 0
From date of first study treatment until date of first confirmed response (CR or PR). The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Secondary outcome [26] 0 0
Change From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study
Timepoint [26] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [27] 0 0
Change From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study
Timepoint [27] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [28] 0 0
Change From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study
Timepoint [28] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [29] 0 0
Change From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study
Timepoint [29] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [30] 0 0
Change From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study
Timepoint [30] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcome [31] 0 0
Change From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study
Timepoint [31] 0 0
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection
* HER2-positive breast cancer
* Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
* LVEF of at least 50 percent (%)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease
* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (</=) 6 months
* Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
* Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
* History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
* Central nervous system (CNS) metastases
* Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)
* History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
* Inadequate bone marrow, liver or renal function
* Uncontrolled hypertension
* Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/09/2019
Sample size
Target
Accrual to date
Final
1436
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Recruitment hospital [1] 0 0
Canberra Hospital; Medical Oncology - Canberra
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital; Medical Oncology - Camperdown
Recruitment hospital [3] 0 0
HOCA Chermside - Chermside
Recruitment hospital [4] 0 0
Mater Hospital; Cancer Services - South Brisbane
Recruitment hospital [5] 0 0
Austin and Repatriation Medical Centre; Cancer Services - Melbourne
Recruitment hospital [6] 0 0
Royal Melbourne Hospital; Hematology and Medical Oncology - Parkville
Recruitment postcode(s) [1] 0 0
2606 - Canberra
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
3084 - Melbourne
Recruitment postcode(s) [6] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
Algeria
State/province [1] 0 0
Algiers
Country [2] 0 0
Argentina
State/province [2] 0 0
La Rioja
Country [3] 0 0
Argentina
State/province [3] 0 0
Rosario
Country [4] 0 0
Austria
State/province [4] 0 0
Graz
Country [5] 0 0
Austria
State/province [5] 0 0
Innsbruck
Country [6] 0 0
Austria
State/province [6] 0 0
Linz
Country [7] 0 0
Austria
State/province [7] 0 0
Salzburg
Country [8] 0 0
Austria
State/province [8] 0 0
Steyr
Country [9] 0 0
Austria
State/province [9] 0 0
Wien
Country [10] 0 0
Belgium
State/province [10] 0 0
Brussel
Country [11] 0 0
Belgium
State/province [11] 0 0
Edegem
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Belgium
State/province [13] 0 0
Leuven
Country [14] 0 0
Belgium
State/province [14] 0 0
Liège
Country [15] 0 0
Brazil
State/province [15] 0 0
RJ
Country [16] 0 0
Brazil
State/province [16] 0 0
RS
Country [17] 0 0
Brazil
State/province [17] 0 0
SP
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
British Columbia
Country [20] 0 0
Canada
State/province [20] 0 0
Nova Scotia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
China
State/province [23] 0 0
Beijing
Country [24] 0 0
China
State/province [24] 0 0
Chongqing
Country [25] 0 0
China
State/province [25] 0 0
Guangzhou
Country [26] 0 0
China
State/province [26] 0 0
Harbin
Country [27] 0 0
China
State/province [27] 0 0
Nanjing
Country [28] 0 0
China
State/province [28] 0 0
Shanghai
Country [29] 0 0
China
State/province [29] 0 0
Tianjin
Country [30] 0 0
China
State/province [30] 0 0
Xi'an
Country [31] 0 0
Ecuador
State/province [31] 0 0
Portoviejo
Country [32] 0 0
Ecuador
State/province [32] 0 0
Quito
Country [33] 0 0
Egypt
State/province [33] 0 0
Cairo
Country [34] 0 0
Estonia
State/province [34] 0 0
Tallinn
Country [35] 0 0
Estonia
State/province [35] 0 0
Tartu
Country [36] 0 0
Finland
State/province [36] 0 0
Helsinki
Country [37] 0 0
Finland
State/province [37] 0 0
Pori
Country [38] 0 0
Finland
State/province [38] 0 0
Tampere
Country [39] 0 0
Finland
State/province [39] 0 0
Turku
Country [40] 0 0
France
State/province [40] 0 0
Amiens
Country [41] 0 0
France
State/province [41] 0 0
Angers
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux
Country [43] 0 0
France
State/province [43] 0 0
Bourg En Bresse
Country [44] 0 0
France
State/province [44] 0 0
Dechy
Country [45] 0 0
France
State/province [45] 0 0
Dijon
Country [46] 0 0
France
State/province [46] 0 0
Hyeres
Country [47] 0 0
France
State/province [47] 0 0
La Chaussee St Victor
Country [48] 0 0
France
State/province [48] 0 0
LeMans
Country [49] 0 0
France
State/province [49] 0 0
Lille
Country [50] 0 0
France
State/province [50] 0 0
Limoges
Country [51] 0 0
France
State/province [51] 0 0
Lyon
Country [52] 0 0
France
State/province [52] 0 0
Marseille
Country [53] 0 0
France
State/province [53] 0 0
Mougins
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
France
State/province [55] 0 0
Perpignan
Country [56] 0 0
France
State/province [56] 0 0
Reims
Country [57] 0 0
France
State/province [57] 0 0
Rennes
Country [58] 0 0
France
State/province [58] 0 0
Saint Cloud
Country [59] 0 0
France
State/province [59] 0 0
Saint Gregoire
Country [60] 0 0
France
State/province [60] 0 0
Saint Herblain
Country [61] 0 0
France
State/province [61] 0 0
Strasbourg
Country [62] 0 0
France
State/province [62] 0 0
Toulouse
Country [63] 0 0
France
State/province [63] 0 0
Valence
Country [64] 0 0
France
State/province [64] 0 0
Valenciennes
Country [65] 0 0
Germany
State/province [65] 0 0
Bamberg
Country [66] 0 0
Germany
State/province [66] 0 0
Bremen
Country [67] 0 0
Germany
State/province [67] 0 0
Erlangen
Country [68] 0 0
Germany
State/province [68] 0 0
Essen
Country [69] 0 0
Germany
State/province [69] 0 0
Esslingen
Country [70] 0 0
Germany
State/province [70] 0 0
Frankfurt
Country [71] 0 0
Germany
State/province [71] 0 0
Gera
Country [72] 0 0
Germany
State/province [72] 0 0
Hamburg
Country [73] 0 0
Germany
State/province [73] 0 0
Hannover
Country [74] 0 0
Germany
State/province [74] 0 0
Heidelberg
Country [75] 0 0
Germany
State/province [75] 0 0
Homburg/Saar
Country [76] 0 0
Germany
State/province [76] 0 0
Limburg
Country [77] 0 0
Germany
State/province [77] 0 0
Lübeck
Country [78] 0 0
Germany
State/province [78] 0 0
Mönchengladbach
Country [79] 0 0
Germany
State/province [79] 0 0
München
Country [80] 0 0
Germany
State/province [80] 0 0
Neuruppin
Country [81] 0 0
Germany
State/province [81] 0 0
Rotenburg/Wümme
Country [82] 0 0
Germany
State/province [82] 0 0
Saarbruecken
Country [83] 0 0
Germany
State/province [83] 0 0
Torgau
Country [84] 0 0
Germany
State/province [84] 0 0
Tübingen
Country [85] 0 0
Greece
State/province [85] 0 0
Athens
Country [86] 0 0
Greece
State/province [86] 0 0
Crete
Country [87] 0 0
Greece
State/province [87] 0 0
Patras
Country [88] 0 0
Greece
State/province [88] 0 0
Thessaloniki
Country [89] 0 0
Greece
State/province [89] 0 0
????a
Country [90] 0 0
Greece
State/province [90] 0 0
?a??sa
Country [91] 0 0
Hong Kong
State/province [91] 0 0
Hong Kong
Country [92] 0 0
Hungary
State/province [92] 0 0
Budapest
Country [93] 0 0
Hungary
State/province [93] 0 0
Debrecen
Country [94] 0 0
Hungary
State/province [94] 0 0
Miskolc
Country [95] 0 0
Hungary
State/province [95] 0 0
Szeged
Country [96] 0 0
Israel
State/province [96] 0 0
Beer Sheva
Country [97] 0 0
Israel
State/province [97] 0 0
Haifa
Country [98] 0 0
Israel
State/province [98] 0 0
Holon
Country [99] 0 0
Israel
State/province [99] 0 0
Jerusalem
Country [100] 0 0
Israel
State/province [100] 0 0
Nahariya
Country [101] 0 0
Israel
State/province [101] 0 0
Petach Tikva
Country [102] 0 0
Israel
State/province [102] 0 0
Ramat Gan
Country [103] 0 0
Israel
State/province [103] 0 0
Rehovot
Country [104] 0 0
Israel
State/province [104] 0 0
Tel Aviv
Country [105] 0 0
Israel
State/province [105] 0 0
Zerifin
Country [106] 0 0
Italy
State/province [106] 0 0
Campania
Country [107] 0 0
Italy
State/province [107] 0 0
Emilia-Romagna
Country [108] 0 0
Italy
State/province [108] 0 0
Friuli-Venezia Giulia
Country [109] 0 0
Italy
State/province [109] 0 0
Lazio
Country [110] 0 0
Italy
State/province [110] 0 0
Liguria
Country [111] 0 0
Italy
State/province [111] 0 0
Lombardia
Country [112] 0 0
Italy
State/province [112] 0 0
Marche
Country [113] 0 0
Italy
State/province [113] 0 0
Piemonte
Country [114] 0 0
Italy
State/province [114] 0 0
Sicilia
Country [115] 0 0
Italy
State/province [115] 0 0
Toscana
Country [116] 0 0
Italy
State/province [116] 0 0
Veneto
Country [117] 0 0
Lebanon
State/province [117] 0 0
Beirut
Country [118] 0 0
Lithuania
State/province [118] 0 0
Kaunas
Country [119] 0 0
Lithuania
State/province [119] 0 0
Vilnius
Country [120] 0 0
Mexico
State/province [120] 0 0
D.f.
Country [121] 0 0
Mexico
State/province [121] 0 0
Distrito Federal
Country [122] 0 0
Mexico
State/province [122] 0 0
Mexico City
Country [123] 0 0
Mexico
State/province [123] 0 0
Mexico DF
Country [124] 0 0
Mexico
State/province [124] 0 0
Queretaro, Queretaro
Country [125] 0 0
Morocco
State/province [125] 0 0
Rabat
Country [126] 0 0
Netherlands
State/province [126] 0 0
Alkmaar
Country [127] 0 0
Netherlands
State/province [127] 0 0
Dordrecht
Country [128] 0 0
Netherlands
State/province [128] 0 0
Eindhoven
Country [129] 0 0
Netherlands
State/province [129] 0 0
Groningen
Country [130] 0 0
Netherlands
State/province [130] 0 0
Leidschendam
Country [131] 0 0
Netherlands
State/province [131] 0 0
Rotterdam
Country [132] 0 0
Netherlands
State/province [132] 0 0
Tilburg
Country [133] 0 0
Netherlands
State/province [133] 0 0
Venlo
Country [134] 0 0
Pakistan
State/province [134] 0 0
Islamabad
Country [135] 0 0
Pakistan
State/province [135] 0 0
Lahore
Country [136] 0 0
Peru
State/province [136] 0 0
Lima
Country [137] 0 0
Poland
State/province [137] 0 0
Bialystok
Country [138] 0 0
Poland
State/province [138] 0 0
Kielce
Country [139] 0 0
Poland
State/province [139] 0 0
Kraków
Country [140] 0 0
Poland
State/province [140] 0 0
Lodz
Country [141] 0 0
Poland
State/province [141] 0 0
Otwock
Country [142] 0 0
Poland
State/province [142] 0 0
Warszawa
Country [143] 0 0
Portugal
State/province [143] 0 0
Coimbra
Country [144] 0 0
Portugal
State/province [144] 0 0
Evora
Country [145] 0 0
Portugal
State/province [145] 0 0
Lisboa
Country [146] 0 0
Portugal
State/province [146] 0 0
Loures
Country [147] 0 0
Portugal
State/province [147] 0 0
Porto
Country [148] 0 0
Saudi Arabia
State/province [148] 0 0
Riyadh
Country [149] 0 0
Serbia
State/province [149] 0 0
Belgrade
Country [150] 0 0
Serbia
State/province [150] 0 0
Sremska Kamenica
Country [151] 0 0
Slovenia
State/province [151] 0 0
Ljubljana
Country [152] 0 0
Spain
State/province [152] 0 0
Alicante
Country [153] 0 0
Spain
State/province [153] 0 0
Asturias
Country [154] 0 0
Spain
State/province [154] 0 0
Barcelona
Country [155] 0 0
Spain
State/province [155] 0 0
Cadiz
Country [156] 0 0
Spain
State/province [156] 0 0
Castellon
Country [157] 0 0
Spain
State/province [157] 0 0
Huesca
Country [158] 0 0
Spain
State/province [158] 0 0
Islas Baleares
Country [159] 0 0
Spain
State/province [159] 0 0
LA Coruña
Country [160] 0 0
Spain
State/province [160] 0 0
LA Rioja
Country [161] 0 0
Spain
State/province [161] 0 0
LAS Palmas
Country [162] 0 0
Spain
State/province [162] 0 0
Madrid
Country [163] 0 0
Spain
State/province [163] 0 0
Navarra
Country [164] 0 0
Spain
State/province [164] 0 0
Tarragona
Country [165] 0 0
Spain
State/province [165] 0 0
Tenerife
Country [166] 0 0
Spain
State/province [166] 0 0
Valencia
Country [167] 0 0
Spain
State/province [167] 0 0
Vizcaya
Country [168] 0 0
Spain
State/province [168] 0 0
Burgos
Country [169] 0 0
Spain
State/province [169] 0 0
Caceres
Country [170] 0 0
Spain
State/province [170] 0 0
Girona
Country [171] 0 0
Spain
State/province [171] 0 0
Granada
Country [172] 0 0
Spain
State/province [172] 0 0
Guadalajara
Country [173] 0 0
Spain
State/province [173] 0 0
Leon
Country [174] 0 0
Spain
State/province [174] 0 0
Malaga
Country [175] 0 0
Spain
State/province [175] 0 0
Murcia
Country [176] 0 0
Spain
State/province [176] 0 0
Orense
Country [177] 0 0
Spain
State/province [177] 0 0
Salamanca
Country [178] 0 0
Spain
State/province [178] 0 0
Sevilla
Country [179] 0 0
Spain
State/province [179] 0 0
Valladolid
Country [180] 0 0
Spain
State/province [180] 0 0
Zaragoza
Country [181] 0 0
Sweden
State/province [181] 0 0
Gävle
Country [182] 0 0
Sweden
State/province [182] 0 0
Göteborg
Country [183] 0 0
Sweden
State/province [183] 0 0
Karlstad
Country [184] 0 0
Sweden
State/province [184] 0 0
Lund
Country [185] 0 0
Sweden
State/province [185] 0 0
Vaxjo
Country [186] 0 0
Sweden
State/province [186] 0 0
Västerås
Country [187] 0 0
Turkey
State/province [187] 0 0
Adana
Country [188] 0 0
Turkey
State/province [188] 0 0
Antalya
Country [189] 0 0
Turkey
State/province [189] 0 0
Bornova, I?zmi?r
Country [190] 0 0
Turkey
State/province [190] 0 0
Edirne
Country [191] 0 0
Turkey
State/province [191] 0 0
Sihhiye/Ankara
Country [192] 0 0
Ukraine
State/province [192] 0 0
Dnipropetrovsk
Country [193] 0 0
Ukraine
State/province [193] 0 0
Kiev
Country [194] 0 0
Ukraine
State/province [194] 0 0
Lviv
Country [195] 0 0
Ukraine
State/province [195] 0 0
Zaporozhye
Country [196] 0 0
United Arab Emirates
State/province [196] 0 0
Al Ain
Country [197] 0 0
United Kingdom
State/province [197] 0 0
Bath
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Birmingham
Country [199] 0 0
United Kingdom
State/province [199] 0 0
Bristol
Country [200] 0 0
United Kingdom
State/province [200] 0 0
Cambridge
Country [201] 0 0
United Kingdom
State/province [201] 0 0
Cardiff
Country [202] 0 0
United Kingdom
State/province [202] 0 0
Coventry
Country [203] 0 0
United Kingdom
State/province [203] 0 0
Derby
Country [204] 0 0
United Kingdom
State/province [204] 0 0
Durham
Country [205] 0 0
United Kingdom
State/province [205] 0 0
East Kilbride
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Eastbourne
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Glasgow
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Grimsby
Country [209] 0 0
United Kingdom
State/province [209] 0 0
Guildford
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Leeds
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Lindley
Country [212] 0 0
United Kingdom
State/province [212] 0 0
London
Country [213] 0 0
United Kingdom
State/province [213] 0 0
Macclesfield
Country [214] 0 0
United Kingdom
State/province [214] 0 0
Manchester
Country [215] 0 0
United Kingdom
State/province [215] 0 0
Middlesborough
Country [216] 0 0
United Kingdom
State/province [216] 0 0
New Castle Upon Tyne
Country [217] 0 0
United Kingdom
State/province [217] 0 0
Northwood
Country [218] 0 0
United Kingdom
State/province [218] 0 0
Oxford
Country [219] 0 0
United Kingdom
State/province [219] 0 0
Peterborough
Country [220] 0 0
United Kingdom
State/province [220] 0 0
Plymouth
Country [221] 0 0
United Kingdom
State/province [221] 0 0
Somerset
Country [222] 0 0
United Kingdom
State/province [222] 0 0
Sutton
Country [223] 0 0
United Kingdom
State/province [223] 0 0
Truro
Country [224] 0 0
United Kingdom
State/province [224] 0 0
Wishaw
Country [225] 0 0
Uruguay
State/province [225] 0 0
Montevideo
Country [226] 0 0
Venezuela
State/province [226] 0 0
Caracas

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
Trial website
https://clinicaltrials.gov/study/NCT01572038
Trial related presentations / publications
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01572038